KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Revenue (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Revenue for 11 consecutive years, with $7.5 million as the latest value for Q1 2025.

  • On a quarterly basis, Revenue changed N/A to $7.5 million in Q1 2025 year-over-year; TTM through Dec 2025 was $7.5 million, a N/A change, with the full-year FY2025 number at $7.5 million, changed N/A from a year prior.
  • Revenue was $7.5 million for Q1 2025 at Xenon Pharmaceuticals, up from $132000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $8.8 million in Q1 2022 to a low of $132000.0 in Q3 2022.
  • A 3-year average of $4.0 million and a median of $4.0 million in 2021 define the central range for Revenue.
  • Biggest YoY gain for Revenue was 101.15% in 2022; the steepest drop was 97.07% in 2022.
  • Xenon Pharmaceuticals' Revenue stood at $3.7 million in 2021, then tumbled by 96.47% to $132000.0 in 2022, then soared by 5581.82% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Revenue are $7.5 million (Q1 2025), $132000.0 (Q3 2022), and $536000.0 (Q2 2022).